Worldwide orphan drug sales forecast to total $178bn in 2020
EvaluatePharma has just released their Orphan Drug Report 2015. This free report contains tons of great information on the current state of the market. A few highlights below: - Median cost per patient differential is 13.8 times higher for orphan drugs compared to non-orphan - Phase III orphan drug development costs half that of non-orphan but Phase III drug development - Worldwide orphan drug sales forecast to total $178bn (CAGR 2015 to 2020: +11.7%); nearly double the ove
FDA Comments on Recently Released Rare Disease Guidance for Industry
Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently released draft guidance for industry on rare disease drug development. Given the complexity and challenges of developing and bringing to market new FDA-approved drugs to treat rare diseases, we're excited to see this topic garnering more support. Read more here: http://blogs.fda.gov/fdavoice/index.php/2015/09/another-tool-help
